Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As ᅢᄁ¬ツᆲᅤモthe dormancy company,ᅢᄁ¬ツᆲᅡン we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.